Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octofluo
- Development stage
- Preclinical
- Lead developer
- Philochem
- Modality
- Peptides
- Administration
- Intravenous, Intratumoral
01
Overview
Octofluo (also referred to as Octo-Fluo) is a novel fluorescein-conjugated somatostatin receptor type 2 (SSTR2) antagonist peptide developed as a bispecific adapter for chimeric antigen receptor (CAR) T-cell therapy. It consists of a high-avidity octameric SSTR2 antagonist peptide linked to fluorescein-5-isothiocyanate (FITC). Octofluo acts as an on-off tunable activating bridge, redirecting FITC-specific adapter CAR-T cells (AdFITC(E2)-CAR T-cells) to SSTR2-expressing tumor cells. It has shown preclinical efficacy in SSTR2-positive malignancies, including meningiomas, gliomas, and neuroendocrine tumors.
- Other names
- Octo-FluoOcto-Fluo bispecific adaptoroctofluo bispecific adaptor
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on octofluo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on octofluo.